A 50-year-old female patient with a past medical history of hypertension presented with shortness of breath for the prior two days. Physical examination was significant for bilateral wheezing, but otherwise was within normal limits. Chest X-ray study (Fig. 1a) showed diffuse calcified pulmonary nodules throughout both lung fields, greater on the left. CT scan of the chest (Fig. 1b) was significant for numerous bilateral pulmonary nodules, most of which were heavily calcified.
The differential diagnosis for calcified pulmonary nodules includes a broad spectrum of etiologies, the most important being neoplastic and infectious [1] . These include but are not limited to tuberculosis, pulmonary amyloidosis, lymphoma or lung metastasis. In this case the diagnosis was pulmonary amyloidosis.
Pulmonary amyloidosis This disease is characterized by extracellular deposition of fibrillary proteins in the lung. It is a difficult diagnosis due to its diverse clinical presentation [1, 2] , with respiratory involvement being demonstrated in 50% of patients [3] .
The CT scan is helpful in the demonstration of subtle calcification that is often the only suggestive sign of this diagnosis [1, 4] , but tissue biopsy is essential for definitive diagnosis [2] with histological confirmation showing amyloid that is a proteinaceous, homogeneous, acellular, and eosinophilic material that shows green birefringence under polarized light when subjected to histochemical staining with Congo red [4] .
Endobronchial ultrasonography (EBUS) uses an ultrasound probe that is inserted into the trachea and bronchial lumen to achieve images through real-time scanning of the trachea, bronchial wall layers and surrounding organs and vessels [5] . The EBUS convex probe is used for biopsies under real-time monitoring, and thus improves the accuracy and safety of the procedure, as well as its ability to reach peripheral lung nodules [5] . In this case, EBUS would show multiple echogenic foci of calcification with or without posterior shadowing [6, 7] .
The goal of therapy is to suppress the plasma cell clones responsible for the synthesis of light chain immunoglobulin, and thus allow the body to dissolve and eliminate the amyloid deposits. Once proven via biopsy, patients with a visceral syndrome are candidates for therapy with either stem cell transplantation or chemotherapy. In our patient, she underwent biopsy that proved the diagnosis of pulmonary amyloidosis.
The patient was admitted and received Melphalan an alkylating agent that inhibits protein synthesis along with a course of dexamethasone with only mild improvement. The patient was scheduled to follow-up with pulmonary as an outpatient, but was lost to follow up.
